{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:49:17Z","timestamp":1794588557168,"version":"4.9.1"},"reference-count":283,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41573-025-01165-w","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:52Z","timestamp":1743811252000},"page":"589-609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Biomarker-guided decision making in clinical drug development for neurodegenerative disorders"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-4158","authenticated-orcid":false,"given":"Jeffrey L.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8797-2042","authenticated-orcid":false,"given":"Brian K.","family":"Fiske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Le Ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin R.","family":"Wildsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7800-1781","authenticated-orcid":false,"given":"Michael","family":"Sch\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"1165_CR1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-019-0529-5","volume":"11","author":"J Cummings","year":"2019","unstructured":"Cummings, J., Feldman, H. H. & Scheltens, P. The \u201crights\u201d of precision drug development for Alzheimer\u2019s disease. Alzheimers Res. Ther. 11, 76 (2019).","journal-title":"Alzheimers Res. Ther."},{"key":"1165_CR2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/17460441.2017.1380623","volume":"12","author":"ECM de Lange","year":"2017","unstructured":"de Lange, E. C. M., van den Brink, W., Yamamoto, Y., de Witte, W. E. A. & Wong, Y. C. Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics. Expert Opin. Drug Discov. 12, 1207\u20131218 (2017).","journal-title":"Expert Opin. Drug Discov."},{"key":"1165_CR3","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40262-018-0632-y","volume":"57","author":"N Srinivas","year":"2018","unstructured":"Srinivas, N., Maffuid, K. & Kashuba, A. D. M. Clinical pharmacokinetics and pharmacodynamics of drugs in the central nervous system. Clin. Pharmacokinet. 57, 1059\u20131074 (2018).","journal-title":"Clin. Pharmacokinet."},{"key":"1165_CR4","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators.","year":"2022","unstructured":"GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7, e105\u2013e125 (2022).","journal-title":"Lancet Public Health"},{"key":"1165_CR5","doi-asserted-by":"publisher","first-page":"fcae183","DOI":"10.1093\/braincomms\/fcae183","volume":"6","author":"N Corriveau-Lecavalier","year":"2024","unstructured":"Corriveau-Lecavalier, N. et al. Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome. Brain Commun. 6, fcae183 (2024).","journal-title":"Brain Commun."},{"key":"1165_CR6","doi-asserted-by":"publisher","first-page":"04160","DOI":"10.7189\/jogh.13.04160","volume":"13","author":"Y Huang","year":"2023","unstructured":"Huang, Y., Li, Y., Pan, H. & Han, L. Global, regional, and national burden of neurological disorders in 204 countries and territories worldwide. J. Glob. Health 13, 04160 (2023).","journal-title":"J. Glob. Health"},{"key":"1165_CR7","unstructured":"FDA\u2013NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/ (FDA\u2013NIH, 2021)."},{"key":"1165_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41582-020-0348-0","volume":"16","author":"NJ Ashton","year":"2020","unstructured":"Ashton, N. J. et al. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat. Rev. Neurol. 16, 265\u2013284 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"1165_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/bs.acc.2022.09.006","volume":"112","author":"J Simren","year":"2023","unstructured":"Simren, J., Elmgren, A., Blennow, K. & Zetterberg, H. Fluid biomarkers in Alzheimer\u2019s disease. Adv. Clin. Chem. 112, 249\u2013281 (2023).","journal-title":"Adv. Clin. Chem."},{"key":"1165_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2174\/138945010791011947","volume":"11","author":"DJ Hunter","year":"2010","unstructured":"Hunter, D. J. et al. A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. Curr. Drug Targets 11, 536\u2013545 (2010).","journal-title":"Curr. Drug Targets"},{"key":"1165_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fneur.2015.00179","volume":"6","author":"U Andreasson","year":"2015","unstructured":"Andreasson, U. et al. A practical guide to immunoassay method validation. Front. Neurol. 6, 179 (2015).","journal-title":"Front. Neurol."},{"key":"1165_CR12","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.3233\/JPD-202428","volume":"11","author":"D Stephenson","year":"2021","unstructured":"Stephenson, D., Badawy, R., Mathur, S., Tome, M. & Rochester, L. Digital progression biomarkers as novel endpoints in clinical trials: a multistakeholder perspective. J. Parkinsons Dis. 11, S103\u2013S109 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"1165_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1535370217750088","volume":"243","author":"RM Califf","year":"2018","unstructured":"Califf, R. M. Biomarker definitions and their applications. Exp. Biol. Med. 243, 213\u2013221 (2018).","journal-title":"Exp. Biol. Med."},{"key":"1165_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrd4309","volume":"13","author":"D Cook","year":"2014","unstructured":"Cook, D. et al. Lessons learned from the fate of AstraZeneca\u2019s drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419\u2013431 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1165_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd.2017.244","volume":"17","author":"P Morgan","year":"2018","unstructured":"Morgan, P. et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat. Rev. Drug Discov. 17, 167\u2013181 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1165_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273\u2013286 (2019).","journal-title":"Biostatistics"},{"key":"1165_CR17","doi-asserted-by":"publisher","first-page":"117727192097465","DOI":"10.1177\/1177271920974652","volume":"15","author":"M Gromova","year":"2020","unstructured":"Gromova, M., Vaggelas, A., Dallmann, G. & Seimetz, D. Biomarkers: opportunities and challenges for drug development in the current regulatory landscape. Biomark Insights 15, 1177271920974652 (2020).","journal-title":"Biomark Insights"},{"key":"1165_CR18","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1111\/ejn.15619","volume":"56","author":"J Cummings","year":"2022","unstructured":"Cummings, J., Ortiz, A., Castellino, J. & Kinney, J. Diabetes: risk factor and translational therapeutic implications for Alzheimer\u2019s disease. Eur. J. Neurosci. 56, 5727\u20135757 (2022).","journal-title":"Eur. J. Neurosci."},{"key":"1165_CR19","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1136\/jnnp-2020-322987","volume":"91","author":"TP Tavares","year":"2020","unstructured":"Tavares, T. P. et al. Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. J. Neurol. Neurosurg. Psychiatry 91, 975\u2013984 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1165_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3233\/JPD-230376","volume":"14","author":"SY Lim","year":"2024","unstructured":"Lim, S. Y. & Klein, C. Parkinson\u2019s disease is predominantly a genetic disease. J. Parkinsons Dis. 14, 467\u2013482 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"1165_CR21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C. & Bu, G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat. Rev. Neurol. 15, 501\u2013518 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"1165_CR22","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/alz.13532","volume":"20","author":"ME Riviere","year":"2024","unstructured":"Riviere, M. E. et al. Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE epsilon4 homozygotes. Alzheimers Dement. 20, 1839\u20131850 (2024).","journal-title":"Alzheimers Dement."},{"key":"1165_CR23","first-page":"216","volume":"5","author":"C Lopez Lopez","year":"2019","unstructured":"Lopez Lopez, C. et al. The Alzheimer\u2019s prevention initiative generation program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer\u2019s disease. Alzheimers Dement. 5, 216\u2013227 (2019).","journal-title":"Alzheimers Dement."},{"key":"1165_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40035-020-00218-x","volume":"9","author":"CU von Linstow","year":"2020","unstructured":"von Linstow, C. U., Gan-Or, Z. & Brundin, P. Precision medicine in Parkinson\u2019s disease patients with LRRK2 and GBA risk variants \u2013 let\u2019s get even more personal. Transl. Neurodegener. 9, 39 (2020).","journal-title":"Transl. Neurodegener."},{"key":"1165_CR25","unstructured":"Brockmann, K. & Gasser, T. Prevention of Dementia in GBA-Associated Parkinson\u2019s Disease https:\/\/www.michaeljfox.org\/grant\/prevention-dementia-gba-associated-parkinsons-disease (Michael J. Fox Foundation for Parkinson\u2019s Research, 2023)."},{"key":"1165_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/JPD-130192","volume":"3","author":"C Pais\u00e1n-Ruiz","year":"2013","unstructured":"Pais\u00e1n-Ruiz, C., Lewis, P. A. & Singleton, A. B. LRRK2: cause, risk, and mechanism. J. Parkinsons Dis. 3, 85\u2013103 (2013).","journal-title":"J. Parkinsons Dis."},{"key":"1165_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41531-023-00544-7","volume":"9","author":"JM Taymans","year":"2023","unstructured":"Taymans, J. M. et al. Perspective on the current state of the LRRK2 field. NPJ Parkinsons Dis. 9, 104 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1165_CR28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tins.2021.12.002","volume":"45","author":"EM Rocha","year":"2022","unstructured":"Rocha, E. M., Keeney, M. T., Di Maio, R., De Miranda, B. R. & Greenamyre, J. T. LRRK2 and idiopathic Parkinson\u2019s disease. Trends Neurosci. 45, 224\u2013236 (2022).","journal-title":"Trends Neurosci."},{"key":"1165_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/14728222.2020.1733970","volume":"24","author":"Y Chen","year":"2020","unstructured":"Chen, Y. et al. Glucocerebrosidase as a therapeutic target for Parkinson\u2019s disease. Expert Opin. Ther. Targets 24, 287\u2013294 (2020).","journal-title":"Expert Opin. Ther. Targets"},{"key":"1165_CR30","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1474-4422(23)00283-1","volume":"22","author":"M Rizig","year":"2023","unstructured":"Rizig, M. et al. Identification of genetic risk loci and causal insights associated with Parkinson\u2019s disease in African and African admixed populations: a genome-wide association study. Lancet Neurol. 22, 1015\u20131025 (2023).","journal-title":"Lancet Neurol."},{"key":"1165_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings, D. et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci. Transl. Med. 14, eabj2658 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1165_CR32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","volume":"22","author":"N Giladi","year":"2023","unstructured":"Giladi, N. et al. Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 22, 661\u2013671 (2023).","journal-title":"Lancet Neurol."},{"key":"1165_CR33","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00415-019-09363-4","volume":"266","author":"CV Greaves","year":"2019","unstructured":"Greaves, C. V. & Rohrer, J. D. An update on genetic frontotemporal dementia. J. Neurol. 266, 2075\u20132086 (2019).","journal-title":"J. Neurol."},{"key":"1165_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30675-z","volume":"13","author":"AC Fahed","year":"2022","unstructured":"Fahed, A. C., Philippakis, A. A. & Khera, A. V. The potential of polygenic scores to improve cost and efficiency of clinical trials. Nat. Commun. 13, 2922 (2022).","journal-title":"Nat. Commun."},{"key":"1165_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091\u20131102 (2019).","journal-title":"Lancet Neurol."},{"key":"1165_CR36","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S1474-4422(15)00178-7","volume":"14","author":"MA Nalls","year":"2015","unstructured":"Nalls, M. A. et al. Diagnosis of Parkinson\u2019s disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol. 14, 1002\u20131009 (2015).","journal-title":"Lancet Neurol."},{"key":"1165_CR37","first-page":"164","volume":"5","author":"C Ballard","year":"2019","unstructured":"Ballard, C. et al. Enrichment factors for clinical trials in mild-to-moderate Alzheimer\u2019s disease. Alzheimers Dement. 5, 164\u2013174 (2019).","journal-title":"Alzheimers Dement."},{"key":"1165_CR38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J. Prev. Alzheimer\u2019s Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"1165_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1165_CR40","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"1165_CR41","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","volume":"63","author":"M Chapleau","year":"2022","unstructured":"Chapleau, M., Iaccarino, L., Soleimani-Meigooni, D. & Rabinovici, G. D. The role of amyloid PET in imaging neurodegenerative disorders: a review. J. Nucl. Med. 63, 13S\u201319S (2022).","journal-title":"J. Nucl. Med."},{"key":"1165_CR42","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1007\/s00259-023-06279-0","volume":"50","author":"A Jovalekic","year":"2023","unstructured":"Jovalekic, A. et al. Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods. Eur. J. Nucl. Med. Mol. Imaging 50, 3276\u20133289 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1165_CR43","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00259-020-04942-4","volume":"48","author":"BJ Hanseeuw","year":"2021","unstructured":"Hanseeuw, B. J. et al. Defining a centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [(18)F] flutemetamol amyloid PET study. Eur. J. Nucl. Med. Mol. Imaging 48, 302\u2013310 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1165_CR44","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1002\/alz.13908","volume":"20","author":"A Leuzy","year":"2024","unstructured":"Leuzy, A. et al. Harmonizing tau positron emission tomography in Alzheimer\u2019s disease: the CenTauR scale and the joint propagation model. Alzheimers Dement. 20, 5833\u20135848 (2024).","journal-title":"Alzheimers Dement."},{"key":"1165_CR45","volume":"9","author":"S Shcherbinin","year":"2023","unstructured":"Shcherbinin, S. et al. Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer\u2019s disease. Alzheimers Dement. 9, e12415 (2023).","journal-title":"Alzheimers Dement."},{"key":"1165_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0284182","volume":"18","author":"RG Gatto","year":"2023","unstructured":"Gatto, R. G. et al. Comparative assessment of regional tau distribution by Tau-PET and post-mortem neuropathology in a representative set of Alzheimer\u2019s & frontotemporal lobar degeneration patients. PLoS ONE 18, e0284182 (2023).","journal-title":"PLoS ONE"},{"key":"1165_CR47","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel, H. et al. The amyloid-beta pathway in Alzheimer\u2019s disease. Mol. Psychiatry 26, 5481\u20135503 (2021).","journal-title":"Mol. Psychiatry"},{"key":"1165_CR48","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Suarez-Calvet","year":"2020","unstructured":"Suarez-Calvet, M. et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in Abeta pathology are detected. EMBO Mol. Med. 12, e12921 (2020).","journal-title":"EMBO Mol. Med."},{"key":"1165_CR49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 21, 66\u201377 (2022).","journal-title":"Lancet Neurol."},{"key":"1165_CR50","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","volume":"271","author":"AJ Mendes","year":"2024","unstructured":"Mendes, A. J. et al. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J. Neurol. 271, 2053\u20132066 (2024).","journal-title":"J. Neurol."},{"key":"1165_CR51","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1002\/alz.13026","volume":"19","author":"J Therriault","year":"2023","unstructured":"Therriault, J. et al. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. 19, 4967\u20134977 (2023).","journal-title":"Alzheimers Dement."},{"key":"1165_CR52","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 81, 255\u2013263 (2024).","journal-title":"JAMA Neurol."},{"key":"1165_CR53","doi-asserted-by":"publisher","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","volume":"102","author":"J Therriault","year":"2024","unstructured":"Therriault, J. et al. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer\u2019s pathology. EBioMedicine 102, 105046 (2024).","journal-title":"EBioMedicine"},{"key":"1165_CR54","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler, S. E. et al. Acceptable performance of blood biomarker tests of amyloid pathology-recommendations from the Global CEO Initiative on Alzheimer\u2019s disease. Nat. Rev. Neurol. 20, 426\u2013439 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"1165_CR55","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","volume":"71","author":"S Palmqvist","year":"2014","unstructured":"Palmqvist, S. et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 71, 1282\u20131289 (2014).","journal-title":"JAMA Neurol."},{"key":"1165_CR56","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/alz.13542","volume":"20","author":"RA Rissman","year":"2024","unstructured":"Rissman, R. A. et al. Plasma Abeta42\/Abeta40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 20, 1214\u20131224 (2024).","journal-title":"Alzheimers Dement."},{"key":"1165_CR57","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat. Med. 26, 387\u2013397 (2020).","journal-title":"Nat. Med."},{"key":"1165_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34129-4","volume":"13","author":"A Pichet Binette","year":"2022","unstructured":"Pichet Binette, A. et al. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer\u2019s disease. Nat. Commun. 13, 6635 (2022).","journal-title":"Nat. Commun."},{"key":"1165_CR59","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1002\/alz.13393","volume":"19","author":"PCL Ferreira","year":"2023","unstructured":"Ferreira, P. C. L. et al. Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals. Alzheimers Dement. 19, 4463\u20134474 (2023).","journal-title":"Alzheimers Dement."},{"key":"1165_CR60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barthelemy","year":"2020","unstructured":"Barthelemy, N. R., Horie, K., Sato, C. & Bateman, R. J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J. Exp. Med. 217, e20200861 (2020).","journal-title":"J. Exp. Med."},{"key":"1165_CR61","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault, J. et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 80, 188\u2013199 (2023).","journal-title":"JAMA Neurol."},{"key":"1165_CR62","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat. Med. 29, 1954\u20131963 (2023).","journal-title":"Nat. Med."},{"key":"1165_CR63","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain 143, 3234\u20133241 (2020).","journal-title":"Brain"},{"key":"1165_CR64","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/ana.26620","volume":"93","author":"K Horie","year":"2023","unstructured":"Horie, K. et al. Change in cerebrospinal fluid tau microtubule binding region detects symptom onset, cognitive decline, tangles, and atrophy in dominantly inherited Alzheimer\u2019s disease. Ann. Neurol. 93, 1158\u20131172 (2023).","journal-title":"Ann. Neurol."},{"key":"1165_CR65","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack, C. R. Jr. et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimers Dement."},{"key":"1165_CR66","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","volume":"13","author":"RJ Bateman","year":"2017","unstructured":"Bateman, R. J. et al. The DIAN-TU next generation Alzheimer\u2019s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 13, 8\u201319 (2017).","journal-title":"Alzheimers Dement."},{"key":"1165_CR67","volume":"14","author":"G Wang","year":"2022","unstructured":"Wang, G. et al. Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Alzheimers Dement. 14, e12367 (2022).","journal-title":"Alzheimers Dement."},{"key":"1165_CR68","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"S Salloway","year":"2021","unstructured":"Salloway, S. et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat. Med. 27, 1187\u20131196 (2021).","journal-title":"Nat. Med."},{"key":"1165_CR69","first-page":"150","volume":"4","author":"PN Tariot","year":"2018","unstructured":"Tariot, P. N. et al. The Alzheimer\u2019s Prevention Initiative Autosomal-Dominant Alzheimer\u2019s Disease Trial: a study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer\u2019s disease, including a placebo-treated noncarrier cohort. Alzheimers Dement. 4, 150\u2013160 (2018).","journal-title":"Alzheimers Dement."},{"key":"1165_CR70","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","volume":"25","author":"JF Arboleda-Velasquez","year":"2019","unstructured":"Arboleda-Velasquez, J. F. et al. Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report. Nat. Med. 25, 1680\u20131683 (2019).","journal-title":"Nat. Med."},{"key":"1165_CR71","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"1165_CR72","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","volume":"86","author":"G Rizzo","year":"2016","unstructured":"Rizzo, G. et al. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86, 566\u2013576 (2016).","journal-title":"Neurology"},{"key":"1165_CR73","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","volume":"46","author":"DW Dickson","year":"2018","unstructured":"Dickson, D. W. Neuropathology of Parkinson disease. Parkinsonism Relat. Disord. 46, S30\u2013s33 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1165_CR74","doi-asserted-by":"publisher","first-page":"11234","DOI":"10.3390\/ijms222011234","volume":"22","author":"G Palermo","year":"2021","unstructured":"Palermo, G., Giannoni, S., Bellini, G., Siciliano, G. & Ceravolo, R. Dopamine transporter imaging, current status of a potential biomarker: a comprehensive review. Int. J. Mol. Sci. 22, 11234 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1165_CR75","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1590\/0004-282x-anp-2022-s130","volume":"80","author":"RTV Otani","year":"2022","unstructured":"Otani, R. T. V., Yamamoto, J. Y. S., Nunes, D. M., Haddad, M. S. & Parmera, J. B. Magnetic resonance and dopamine transporter imaging for the diagnosis of Parkinson\u00b4s disease: a narrative review. Arq. Neuropsiquiatr. 80, 116\u2013125 (2022).","journal-title":"Arq. Neuropsiquiatr."},{"key":"1165_CR76","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41531-021-00185-8","volume":"7","author":"D Bega","year":"2021","unstructured":"Bega, D. et al. Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis. NPJ Parkinsons Dis. 7, 43 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"1165_CR77","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano, G. et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N. Engl. J. Med. 387, 421\u2013432 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1165_CR78","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang, A. E. et al. Trial of cinpanemab in early Parkinson\u2019s disease. N. Engl. J. Med. 387, 408\u2013420 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1165_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02470-8","volume":"21","author":"RM Hutchison","year":"2021","unstructured":"Hutchison, R. M. et al. Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson\u2019s disease trial. BMC Neurol. 21, 459 (2021).","journal-title":"BMC Neurol."},{"key":"1165_CR80","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1038\/s41591-024-03101-8","volume":"30","author":"P Eijsvogel","year":"2024","unstructured":"Eijsvogel, P. et al. Target engagement and immunogenicity of an active immunotherapeutic targeting pathological alpha-synuclein: a phase 1 placebo-controlled trial. Nat. Med. 30, 2631\u20132640 (2024).","journal-title":"Nat. Med."},{"key":"1165_CR81","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acn3.644","volume":"5","author":"K Marek","year":"2018","unstructured":"Marek, K. et al. The Parkinson\u2019s progression markers initiative (PPMI) \u2013 establishing a PD biomarker cohort. Ann. Clin. Transl. Neurol. 5, 1460\u20131477 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1165_CR82","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3233\/JPD-191648","volume":"9","author":"D Stephenson","year":"2019","unstructured":"Stephenson, D. et al. The qualification of an enrichment biomarker for clinical trials targeting early stages of Parkinson\u2019s disease. J. Parkinsons Dis. 9, 553\u2013563 (2019).","journal-title":"J. Parkinsons Dis."},{"key":"1165_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00943-6","volume":"12","author":"E Wallert","year":"2022","unstructured":"Wallert, E. et al. Comparison of [18F]-FDOPA PET and [123I]-FP-CIT SPECT acquired in clinical practice for assessing nigrostriatal degeneration in patients with a clinically uncertain parkinsonian syndrome. EJNMMI Res. 12, 68 (2022).","journal-title":"EJNMMI Res."},{"key":"1165_CR84","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/mds.27806","volume":"34","author":"B Mollenhauer","year":"2019","unstructured":"Mollenhauer, B. et al. Longitudinal analyses of cerebrospinal fluid \u03b1-synuclein in prodromal and early Parkinson\u2019s disease. Mov. Disord. 34, 1354\u20131364 (2019).","journal-title":"Mov. Disord."},{"key":"1165_CR85","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","volume":"131","author":"JH Kang","year":"2016","unstructured":"Kang, J. H. et al. CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: the Parkinson\u2019s Progression Markers Initiative study. Acta Neuropathol. 131, 935\u2013949 (2016).","journal-title":"Acta Neuropathol."},{"key":"1165_CR86","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"1165_CR87","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","volume":"18","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio, L., Pritzkow, S., Shahnawaz, M., Farris, C. M. & Soto, C. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nat. Protoc. 18, 1179\u20131196 (2023).","journal-title":"Nat. Protoc."},{"key":"1165_CR88","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.13710","volume":"10","author":"A Grossauer","year":"2023","unstructured":"Grossauer, A. et al. \u03b1-synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid-a systematic review and meta-analysis. Mov. Disord. Clin. Pract. 10, 737\u2013747 (2023).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"1165_CR89","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi, A. et al. Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies. Nat. Med. 29, 1448\u20131455 (2023).","journal-title":"Nat. Med."},{"key":"1165_CR90","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209137","volume":"102","author":"RM Hutchison","year":"2024","unstructured":"Hutchison, R. M. et al. Cinpanemab in early Parkinson disease: evaluation of biomarker results from the phase 2 SPARK clinical trial. Neurology 102, e209137 (2024).","journal-title":"Neurology"},{"key":"1165_CR91","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU Hoglinger","year":"2024","unstructured":"Hoglinger, G. U. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"1165_CR92","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"1165_CR93","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamaneurol.2023.4398","volume":"81","author":"S Yan","year":"2024","unstructured":"Yan, S. et al. Neuronally derived extracellular vesicle alpha-synuclein as a serum biomarker for individuals at risk of developing Parkinson disease. JAMA Neurol. 81, 59\u201368 (2024).","journal-title":"JAMA Neurol."},{"key":"1165_CR94","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2312031121","volume":"121","author":"T Gilboa","year":"2024","unstructured":"Gilboa, T. et al. Toward the quantification of alpha-synuclein aggregates with digital seed amplification assays. Proc. Natl Acad. Sci. USA 121, e2312031121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1165_CR95","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00401-024-02706-0","volume":"147","author":"J Rutledge","year":"2024","unstructured":"Rutledge, J. et al. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson\u2019s disease. Acta Neuropathol. 147, 52 (2024).","journal-title":"Acta Neuropathol."},{"key":"1165_CR96","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/ph14090847","volume":"14","author":"S Korat","year":"2021","unstructured":"Korat, S. et al. Alpha-synuclein PET tracer development-an overview about current efforts. Pharmaceuticals 14, 847 (2021).","journal-title":"Pharmaceuticals"},{"key":"1165_CR97","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1016\/j.cell.2023.06.004","volume":"186","author":"J Xiang","year":"2023","unstructured":"Xiang, J. et al. Development of an alpha-synuclein positron emission tomography tracer for imaging synucleinopathies. Cell 186, 3350\u20133367.e3319 (2023).","journal-title":"Cell"},{"key":"1165_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith, R. et al. The \u03b1-synuclein PET tracer [18F]ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat. Commun. 14, 6750 (2023).","journal-title":"Nat. Commun."},{"key":"1165_CR99","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/mds.29186","volume":"37","author":"K Matsuoka","year":"2022","unstructured":"Matsuoka, K. et al. High-contrast imaging of \u03b1-synuclein pathologies in living patients with multiple system atrophy. Mov. Disord. 37, 2159\u20132161 (2022).","journal-title":"Mov. Disord."},{"key":"1165_CR100","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mds.29360","volume":"38","author":"JM den Heijer","year":"2023","unstructured":"den Heijer, J. M. et al. A biomarker study in patients with GBA1-Parkinson\u2019s disease and healthy controls. Mov. Disord. 38, 783\u2013795 (2023).","journal-title":"Mov. Disord."},{"key":"1165_CR101","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jpsychires.2019.03.019","volume":"113","author":"MR Al Shweiki","year":"2019","unstructured":"Al Shweiki, M. R. et al. Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. J. Psychiatr. Res. 113, 137\u2013140 (2019).","journal-title":"J. Psychiatr. Res."},{"key":"1165_CR102","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1002\/alz.12643","volume":"18","author":"M Del Campo","year":"2022","unstructured":"Del Campo, M. et al. New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimers Dement. 18, 2292\u20132307 (2022).","journal-title":"Alzheimers Dement."},{"key":"1165_CR103","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-019-0470-7","volume":"11","author":"RM Tsai","year":"2019","unstructured":"Tsai, R. M. et al. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res. Ther. 11, 13 (2019).","journal-title":"Alzheimers Res. Ther."},{"key":"1165_CR104","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40478-019-0686-6","volume":"7","author":"C Aguero","year":"2019","unstructured":"Aguero, C. et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathology. Commun. 7, 37 (2019).","journal-title":"Acta Neuropathology. Commun."},{"key":"1165_CR105","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00259-022-06065-4","volume":"50","author":"AF Santillo","year":"2023","unstructured":"Santillo, A. F. et al. [18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes. Eur. J. Nucl. Med. Mol. Imaging 50, 1371\u20131383 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1165_CR106","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/s41591-024-02937-4","volume":"30","author":"M Chatterjee","year":"2024","unstructured":"Chatterjee, M. et al. Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS. Nat. Med. 30, 1771\u20131783 (2024).","journal-title":"Nat. Med."},{"key":"1165_CR107","doi-asserted-by":"publisher","first-page":"fcaa142","DOI":"10.1093\/braincomms\/fcaa142","volume":"2","author":"C Scialo","year":"2020","unstructured":"Scialo, C. et al. TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients. Brain Commun. 2, fcaa142 (2020).","journal-title":"Brain Commun."},{"key":"1165_CR108","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/alz.13541","volume":"20","author":"E Fontana","year":"2023","unstructured":"Fontana, E. et al. Detection of TDP-43 seeding activity in the olfactory mucosa from patients with frontotemporal dementia. Alzheimers Dement. 20, 1156\u20131165 (2023).","journal-title":"Alzheimers Dement."},{"key":"1165_CR109","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13024-023-00608-5","volume":"18","author":"PR Mehta","year":"2023","unstructured":"Mehta, P. R., Brown, A. L., Ward, M. E. & Fratta, P. The era of cryptic exons: implications for ALS-FTD. Mol. Neurodegener. 18, 16 (2023).","journal-title":"Mol. Neurodegener."},{"key":"1165_CR110","doi-asserted-by":"publisher","first-page":"167.e161","DOI":"10.1016\/j.neurobiolaging.2020.02.014","volume":"91","author":"L Sellami","year":"2020","unstructured":"Sellami, L. et al. Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience. Neurobiol. Aging 91, 167.e161\u2013167.e169 (2020).","journal-title":"Neurobiol. Aging"},{"key":"1165_CR111","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13195-024-01420-z","volume":"16","author":"IJ Swift","year":"2024","unstructured":"Swift, I. J. et al. A systematic review of progranulin concentrations in biofluids in over 7,000 people-assessing the pathogenicity of GRN mutations and other influencing factors. Alzheimers Res. Ther. 16, 66 (2024).","journal-title":"Alzheimers Res. Ther."},{"key":"1165_CR112","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller, T. M. et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099\u20131110 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1165_CR113","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J. et al. Targeting huntingtin expression in patients with Huntington\u2019s disease. N. Engl. J. Med. 380, 2307\u20132316 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1165_CR114","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422\u2013433 (2020).","journal-title":"Lancet Neurol."},{"key":"1165_CR115","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/alz.12415","volume":"18","author":"MM Mielke","year":"2022","unstructured":"Mielke, M. M. et al. Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimers Dement. 18, 602\u2013611 (2022).","journal-title":"Alzheimers Dement."},{"key":"1165_CR116","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Differential roles of Abeta42\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat. Med. 28, 2555\u20132562 (2022).","journal-title":"Nat. Med."},{"key":"1165_CR117","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/jnnp-2021-328623","volume":"93","author":"J Lagarde","year":"2022","unstructured":"Lagarde, J. et al. Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer\u2019s disease. J. Neurol. Neurosurg. Psychiatry 93, 459\u2013467 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1165_CR118","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1001\/jamaneurol.2013.3961","volume":"70","author":"RS Wilson","year":"2013","unstructured":"Wilson, R. S. et al. TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol. 70, 1418\u20131424 (2013).","journal-title":"JAMA Neurol."},{"key":"1165_CR119","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1002\/alz.13858","volume":"20","author":"D Tosun","year":"2024","unstructured":"Tosun, D. et al. A cross-sectional study of alpha-synuclein seed amplification assay in Alzheimer\u2019s disease neuroimaging initiative: prevalence and associations with Alzheimer\u2019s disease biomarkers and cognitive function. Alzheimers Dement. 20, 5114\u20135131 (2024).","journal-title":"Alzheimers Dement."},{"key":"1165_CR120","doi-asserted-by":"publisher","first-page":"802","DOI":"10.14283\/jpad.2024.122","volume":"11","author":"RA Sperling","year":"2024","unstructured":"Sperling, R. A. et al. Amyloid and tau prediction of cognitive and functional decline in unimpaired older individuals: longitudinal data from the A4 and LEARN studies. J. Prev. Alzheimers Dis. 11, 802\u2013813 (2024).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1165_CR121","first-page":"668","volume":"3","author":"KV Papp","year":"2017","unstructured":"Papp, K. V., Rentz, D. M., Orlovsky, I., Sperling, R. A. & Mormino, E. C. Optimizing the preclinical Alzheimer\u2019s cognitive composite with semantic processing: the PACC5. Alzheimers Dement. 3, 668\u2013677 (2017).","journal-title":"Alzheimers Dement."},{"key":"1165_CR122","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4088\/JCP.13m08927","volume":"75","author":"N Ayutyanont","year":"2014","unstructured":"Ayutyanont, N. et al. The Alzheimer\u2019s prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer\u2019s disease treatments in presenilin 1 E280A mutation carriers. J. Clin. Psychiatry 75, 652\u2013660 (2014).","journal-title":"J. Clin. Psychiatry"},{"key":"1165_CR123","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/mds.26359","volume":"31","author":"IF Mata","year":"2016","unstructured":"Mata, I. F. et al. GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson\u2019s disease. Mov. Disord. 31, 95\u2013102 (2016).","journal-title":"Mov. Disord."},{"key":"1165_CR124","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamaneurol.2016.2245","volume":"73","author":"MY Davis","year":"2016","unstructured":"Davis, M. Y. et al. Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease. JAMA Neurol. 73, 1217\u20131224 (2016).","journal-title":"JAMA Neurol."},{"key":"1165_CR125","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.nbd.2019.02.023","volume":"127","author":"M Shahid","year":"2019","unstructured":"Shahid, M. et al. An increased rate of longitudinal cognitive decline is observed in Parkinson\u2019s disease patients with low CSF A\u00df42 and an APOE \u03b54 allele. Neurobiol. Dis. 127, 278\u2013286 (2019).","journal-title":"Neurobiol. Dis."},{"key":"1165_CR126","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41531-022-00384-x","volume":"8","author":"L Batzu","year":"2022","unstructured":"Batzu, L. et al. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson\u2019s disease. NPJ Parkinsons Dis. 8, 154 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"1165_CR127","doi-asserted-by":"publisher","first-page":"959261","DOI":"10.3389\/fnins.2022.959261","volume":"16","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Dou, K., Xue, L., Li, X. & Xie, A. Neurofilament light as a biomarker for motor decline in Parkinson\u2019s disease. Front. Neurosci. 16, 959261 (2022).","journal-title":"Front. Neurosci."},{"key":"1165_CR128","doi-asserted-by":"publisher","first-page":"106237","DOI":"10.1016\/j.nbd.2023.106237","volume":"185","author":"D Urso","year":"2023","unstructured":"Urso, D., Batzu, L., Logroscino, G., Ray Chaudhuri, K. & Pereira, J. B. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson\u2019s disease. Neurobiol. Dis. 185, 106237 (2023).","journal-title":"Neurobiol. Dis."},{"key":"1165_CR129","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1212\/WNL.0000000000200384","volume":"99","author":"JM Poos","year":"2022","unstructured":"Poos, J. M. et al. Longitudinal cognitive changes in genetic frontotemporal dementia within the GENFI cohort. Neurology 99, e281\u2013e295 (2022).","journal-title":"Neurology"},{"key":"1165_CR130","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/jnnp-2022-330866","volume":"94","author":"BM Asken","year":"2023","unstructured":"Asken, B. M. et al. Plasma inflammation for predicting phenotypic conversion and clinical progression of autosomal dominant frontotemporal lobar degeneration. J. Neurol. Neurosurg. Psychiatry 94, 541\u2013549 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1165_CR131","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/jnnp-2021-326914","volume":"92","author":"D Saracino","year":"2021","unstructured":"Saracino, D. et al. Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications. J. Neurol. Neurosurg. Psychiatry 92, 1278\u20131288 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1165_CR132","doi-asserted-by":"publisher","first-page":"e2296","DOI":"10.1212\/WNL.0000000000011848","volume":"96","author":"JC Rojas","year":"2021","unstructured":"Rojas, J. C. et al. Plasma neurofilament light for prediction of disease progression in familial frontotemporal lobar degeneration. Neurology 96, e2296\u2013e2312 (2021).","journal-title":"Neurology"},{"key":"1165_CR133","doi-asserted-by":"publisher","first-page":"fcac310","DOI":"10.1093\/braincomms\/fcac310","volume":"5","author":"H Zetterberg","year":"2023","unstructured":"Zetterberg, H. et al. The role of neurofilament light in genetic frontotemporal lobar degeneration. Brain Commun. 5, fcac310 (2023).","journal-title":"Brain Commun."},{"key":"1165_CR134","doi-asserted-by":"publisher","first-page":"e1069","DOI":"10.1212\/WNL.0000000000207581","volume":"101","author":"LAA Giannini","year":"2023","unstructured":"Giannini, L. A. A. et al. Clinical value of longitudinal serum neurofilament light chain in prodromal genetic frontotemporal dementia. Neurology 101, e1069\u2013e1082 (2023).","journal-title":"Neurology"},{"key":"1165_CR135","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1038\/s41591-022-01942-9","volume":"28","author":"AM Staffaroni","year":"2022","unstructured":"Staffaroni, A. M. et al. Temporal order of clinical and biomarker changes in familial frontotemporal dementia. Nat. Med. 28, 2194\u20132206 (2022).","journal-title":"Nat. Med."},{"key":"1165_CR136","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/jnnp-2019-321954","volume":"91","author":"C Heller","year":"2020","unstructured":"Heller, C. et al. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 91, 263\u2013270 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1165_CR137","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1136\/jnnp-2019-322493","volume":"91","author":"EL van der Ende","year":"2020","unstructured":"van der Ende, E. L. et al. Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 91, 612\u2013621 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1165_CR138","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000201292","volume":"99","author":"JM Poos","year":"2022","unstructured":"Poos, J. M. et al. Longitudinal brain atrophy rates in presymptomatic carriers of genetic frontotemporal dementia. Neurology 99, e2661\u2013e2671 (2022).","journal-title":"Neurology"},{"key":"1165_CR139","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/cts.12455","volume":"10","author":"H Scheerens","year":"2017","unstructured":"Scheerens, H. et al. Current status of companion and complementary diagnostics: strategic considerations for development and launch. Clin. Transl. Sci. 10, 84\u201392 (2017).","journal-title":"Clin. Transl. Sci."},{"key":"1165_CR140","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1056\/NEJMc2111960","volume":"385","author":"B Dunn","year":"2021","unstructured":"Dunn, B., Stein, P., Temple, R. & Cavazzoni, P. An appropriate use of accelerated approval \u2013 aducanumab for Alzheimer\u2019s disease. N. Engl. J. Med. 385, 856\u2013857 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1165_CR141","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun, M. A. et al. Donanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 384, 1691\u20131704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1165_CR142","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway, S. et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 79, 13\u201321 (2022).","journal-title":"JAMA Neurol."},{"key":"1165_CR143","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","volume":"4","author":"BM Tijms","year":"2024","unstructured":"Tijms, B. M. et al. Cerebrospinal fluid proteomics in patients with Alzheimer\u2019s disease reveals five molecular subtypes with distinct genetic risk profiles. Nat. Aging 4, 33\u201347 (2024).","journal-title":"Nat. Aging"},{"key":"1165_CR144","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn3504","volume":"16","author":"EB Dammer","year":"2024","unstructured":"Dammer, E. B. et al. Proteomic analysis of Alzheimer\u2019s disease cerebrospinal fluid reveals alterations associated with APOE epsilon4 and atomoxetine treatment. Sci. Transl. Med. 16, eadn3504 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1165_CR145","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mds.29297","volume":"38","author":"D Jennings","year":"2023","unstructured":"Jennings, D. et al. LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson\u2019s disease. Mov. Disord. 38, 386\u2013398 (2023).","journal-title":"Mov. Disord."},{"key":"1165_CR146","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/mds.29346","volume":"38","author":"JM den Heijer","year":"2023","unstructured":"den Heijer, J. M. et al. A phase 1B trial in GBA1-associated Parkinson\u2019s disease of BIA-28-6156, a glucocerebrosidase activator. Mov. Disord. 38, 1197\u20131208 (2023).","journal-title":"Mov. Disord."},{"key":"1165_CR147","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3390\/ijms22041615","volume":"22","author":"M Vissers","year":"2021","unstructured":"Vissers, M., Heuberger, J. & Groeneveld, G. J. Targeting for success: demonstrating proof-of-concept with mechanistic early phase clinical pharmacology studies for disease-modification in neurodegenerative disorders. Int. J. Mol. Sci. 22, 1615 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1165_CR148","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1586\/17512433.2015.991715","volume":"8","author":"WZ Potter","year":"2015","unstructured":"Potter, W. Z. Optimizing early Go\/No Go decisions in CNS drug development. Expert Rev. Clin. Pharmacol. 8, 155\u2013157 (2015).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"1165_CR149","doi-asserted-by":"publisher","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","volume":"8","author":"ME Kennedy","year":"2016","unstructured":"Kennedy, M. E. et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer\u2019s disease patients. Sci. Transl. Med. 8, 363ra150 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1165_CR150","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.21623","volume":"66","author":"RJ Bateman","year":"2009","unstructured":"Bateman, R. J. et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann. Neurol. 66, 48\u201354 (2009).","journal-title":"Ann. Neurol."},{"key":"1165_CR151","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N. Engl. J. Med. 369, 341\u2013350 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1165_CR152","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan, M. F. et al. Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease. N. Engl. J. Med. 380, 1408\u20131420 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1165_CR153","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","volume":"79","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo, M. J. et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 79, 1250\u20131259 (2022).","journal-title":"JAMA Neurol."},{"key":"1165_CR154","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","volume":"1","author":"P Novak","year":"2021","unstructured":"Novak, P. et al. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease. Nat. Aging 1, 521\u2013534 (2021).","journal-title":"Nat. Aging"},{"key":"1165_CR155","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","volume":"29","author":"CJ Mummery","year":"2023","unstructured":"Mummery, C. J. et al. Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat. Med. 29, 1437\u20131447 (2023).","journal-title":"Nat. Med."},{"key":"1165_CR156","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"J Jankovic","year":"2018","unstructured":"Jankovic, J. et al. Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol. 75, 1206\u20131214 (2018).","journal-title":"JAMA Neurol."},{"key":"1165_CR157","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3233\/JPD-191786","volume":"10","author":"S Padmanabhan","year":"2020","unstructured":"Padmanabhan, S. et al. An assessment of LRRK2 serine 935 phosphorylation in human peripheral blood mononuclear cells in idiopathic Parkinson\u2019s disease and G2019S LRRK2 cohorts. J. Parkinsons Dis. 10, 623\u2013629 (2020).","journal-title":"J. Parkinsons Dis."},{"key":"1165_CR158","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12813","volume":"5","author":"M Steger","year":"2016","unstructured":"Steger, M. et al. Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases. eLife 5, e12813 (2016).","journal-title":"eLife"},{"key":"1165_CR159","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/cts.13541","volume":"16","author":"M Vissers","year":"2023","unstructured":"Vissers, M. et al. A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson\u2019s disease with and without LRRK2 mutations and healthy controls. Clin. Transl. Sci. 16, 1408\u20131420 (2023).","journal-title":"Clin. Transl. Sci."},{"key":"1165_CR160","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41531-023-00482-4","volume":"9","author":"S Gomes","year":"2023","unstructured":"Gomes, S. et al. Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson\u2019s disease. NPJ Parkinsons Dis. 9, 52 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1165_CR161","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41531-023-00468-2","volume":"9","author":"KM Merchant","year":"2023","unstructured":"Merchant, K. M. et al. LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts. NPJ Parkinsons Dis. 9, 30 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1165_CR162","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cpdd.865","volume":"10","author":"MJ Peterschmitt","year":"2021","unstructured":"Peterschmitt, M. J. et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers. Clin. Pharmacol. Drug Dev. 10, 86\u201398 (2021).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"1165_CR163","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.25584","volume":"4","author":"PA Ljubenkov","year":"2021","unstructured":"Ljubenkov, P. A. et al. Effect of the histone deacetylase inhibitor FRM-0334 on progranulin levels in patients with progranulin gene haploinsufficiency: a randomized clinical trial. JAMA Netw. Open 4, e2125584 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1165_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04251-y","volume":"21","author":"M Kurnellas","year":"2023","unstructured":"Kurnellas, M. et al. Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia. J. Transl. Med. 21, 387 (2023).","journal-title":"J. Transl. Med."},{"key":"1165_CR165","doi-asserted-by":"publisher","first-page":"859","DOI":"10.15252\/emmm.201607486","volume":"9","author":"C Lehmer","year":"2017","unstructured":"Lehmer, C. et al. Poly-GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS\/FTD. EMBO Mol. Med. 9, 859\u2013868 (2017).","journal-title":"EMBO Mol. Med."},{"key":"1165_CR166","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai7866","volume":"9","author":"TF Gendron","year":"2017","unstructured":"Gendron, T. F. et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci. Transl. Med. 9, eaai7866 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1165_CR167","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/jnnp-2021-328710","volume":"93","author":"KM Wilson","year":"2022","unstructured":"Wilson, K. M. et al. Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 93, 761\u2013771 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1165_CR168","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","volume":"28","author":"H Tran","year":"2022","unstructured":"Tran, H. et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat. Med. 28, 117\u2013124 (2022).","journal-title":"Nat. Med."},{"key":"1165_CR169","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30387-4","volume":"13","author":"G Krishnan","year":"2022","unstructured":"Krishnan, G. et al. Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS\/FTD. Nat. Commun. 13, 2799 (2022).","journal-title":"Nat. Commun."},{"key":"1165_CR170","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208013","volume":"102","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. Investigating white matter neuroinflammation in Alzheimer disease using diffusion-based neuroinflammation imaging. Neurology 102, e208013 (2024).","journal-title":"Neurology"},{"key":"1165_CR171","doi-asserted-by":"publisher","first-page":"45S","DOI":"10.2967\/jnumed.121.263200","volume":"63","author":"JC Masdeu","year":"2022","unstructured":"Masdeu, J. C., Pascual, B. & Fujita, M. Imaging neuroinflammation in neurodegenerative disorders. J. Nucl. Med. 63, 45S\u201352S (2022).","journal-title":"J. Nucl. Med."},{"key":"1165_CR172","doi-asserted-by":"publisher","first-page":"739130","DOI":"10.3389\/fimmu.2021.739130","volume":"12","author":"R Zhou","year":"2021","unstructured":"Zhou, R. et al. PET imaging of neuroinflammation in Alzheimer\u2019s disease. Front. Immunol. 12, 739130 (2021).","journal-title":"Front. Immunol."},{"key":"1165_CR173","volume":"10","author":"SE Arnold","year":"2024","unstructured":"Arnold, S. E. et al. Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer\u2019s disease. Alzheimers Dement. 10, e12487 (2024).","journal-title":"Alzheimers Dement."},{"key":"1165_CR174","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.cell.2017.07.023","volume":"170","author":"TK Ulland","year":"2017","unstructured":"Ulland, T. K. et al. TREM2 maintains microglial metabolic fitness in Alzheimer\u2019s disease. Cell 170, 649\u2013663.e613 (2017).","journal-title":"Cell"},{"key":"1165_CR175","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(23)00247-8","volume":"22","author":"K Schlepckow","year":"2023","unstructured":"Schlepckow, K., Morenas-Rodriguez, E., Hong, S. & Haass, C. Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer\u2019s disease. Lancet Neurol. 22, 1048\u20131060 (2023).","journal-title":"Lancet Neurol."},{"key":"1165_CR176","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158708","volume":"132","author":"A Zhao","year":"2022","unstructured":"Zhao, A. et al. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer\u2019s disease. J Clin Invest 132, e158708 (2022).","journal-title":"J Clin Invest"},{"key":"1165_CR177","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03163-y","volume":"21","author":"S Lista","year":"2024","unstructured":"Lista, S. et al. Tracking neuroinflammatory biomarkers in Alzheimer\u2019s disease: a strategy for individualized therapeutic approaches? J. Neuroinflammation 21, 187 (2024).","journal-title":"J. Neuroinflammation"},{"key":"1165_CR178","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40035-017-0096-2","volume":"6","author":"J Cummings","year":"2017","unstructured":"Cummings, J. Disease modification and neuroprotection in neurodegenerative disorders. Transl. Neurodegener. 6, 25 (2017).","journal-title":"Transl. Neurodegener."},{"key":"1165_CR179","unstructured":"Food and Drug Administration. Early Alzheimer\u2019s Disease: Developing Drugs for Treatment https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/early-alzheimers-disease-developing-drugs-treatment (FDA, 2024)."},{"key":"1165_CR180","first-page":"50","volume":"11","author":"N Bodick","year":"1997","unstructured":"Bodick, N. et al. Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis. Assoc. Disord. 11, 50\u201353 (1997).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"1165_CR181","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1208\/s12248-009-9123-2","volume":"11","author":"VA Bhattaram","year":"2009","unstructured":"Bhattaram, V. A., Siddiqui, O., Kapcala, L. P. & Gobburu, J. V. Endpoints and analyses to discern disease-modifying drug effects in early Parkinson\u2019s disease. AAPS J. 11, 456\u2013464 (2009).","journal-title":"AAPS J."},{"key":"1165_CR182","doi-asserted-by":"publisher","first-page":"103","DOI":"10.14283\/jpad.2018.13","volume":"5","author":"J Cummings","year":"2018","unstructured":"Cummings, J., Fox, N., Vellas, B., Aisen, P. & Shan, G. Biomarker and clinical trial design support for disease-modifying therapies: report of a survey of the EU\/US: Alzheimer\u2019s disease task force. J. Prev. Alzheimers Dis. 5, 103\u2013109 (2018).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1165_CR183","doi-asserted-by":"publisher","first-page":"8","DOI":"10.14283\/jpad.2018.1","volume":"5","author":"H Liu-Seifert","year":"2018","unstructured":"Liu-Seifert, H. et al. Delayed-start analyses in the phase 3 solanezumab EXPEDITION3 study in mild Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 5, 8\u201314 (2018).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1165_CR184","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119632","volume":"10","author":"H Liu-Seifert","year":"2015","unstructured":"Liu-Seifert, H., Andersen, S. W., Lipkovich, I., Holdridge, K. C. & Siemers, E. A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer\u2019s disease. PLoS ONE 10, e0119632 (2015).","journal-title":"PLoS ONE"},{"key":"1165_CR185","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14425","volume":"21","author":"A Elhage","year":"2025","unstructured":"Elhage, A. et al. Defining benefit: clinically and biologically meaningful outcomes in the next-generation Alzheimer\u2019s disease clinical care pathway. Alzheimers Dement. 21, e14425 (2025).","journal-title":"Alzheimers Dement."},{"key":"1165_CR186","doi-asserted-by":"publisher","first-page":"595","DOI":"10.14283\/jpad.2023.50","volume":"10","author":"SP Dickson","year":"2023","unstructured":"Dickson, S. P. et al. \u2018Time Saved\u2019 as a demonstration of clinical meaningfulness and illustrated using the donanemab TRAILBLAZER-ALZ study findings. J. Prev. Alzheimers Dis. 10, 595\u2013599 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1165_CR187","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0606-3","volume":"16","author":"DJ McGhee","year":"2016","unstructured":"McGhee, D. J., Ritchie, C. W., Zajicek, J. P. & Counsell, C. E. A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer\u2019s disease and Parkinson\u2019s disease. BMC Neurol. 16, 92 (2016).","journal-title":"BMC Neurol."},{"key":"1165_CR188","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"RJ Bateman","year":"2023","unstructured":"Bateman, R. J. et al. Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease. N. Engl. J. Med. 389, 1862\u20131876 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1165_CR189","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","volume":"83","author":"J Cummings","year":"2023","unstructured":"Cummings, J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s disease therapeutics. Drugs 83, 569\u2013576 (2023).","journal-title":"Drugs"},{"key":"1165_CR190","first-page":"1797","volume":"28","author":"M Mila-Aloma","year":"2022","unstructured":"Mila-Aloma, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 28, 1797\u20131801 (2022).","journal-title":"Nat. Med."},{"key":"1165_CR191","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00259-021-05191-9","volume":"48","author":"V Dore","year":"2021","unstructured":"Dore, V. et al. Relationship between amyloid and tau levels and its impact on tau spreading. Eur. J. Nucl. Med. Mol. Imaging 48, 2225\u20132232 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1165_CR192","volume":"9","author":"I Gueorguieva","year":"2023","unstructured":"Gueorguieva, I. et al. Donanemab exposure and efficacy relationship using modeling in Alzheimer\u2019s disease. Alzheimers Dement. 9, e12404 (2023).","journal-title":"Alzheimers Dement."},{"key":"1165_CR193","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3233\/JAD-220515","volume":"90","author":"F Roveta","year":"2022","unstructured":"Roveta, F. et al. Synaptic proteins as fluid biomarkers in Alzheimer\u2019s disease: a systematic review and meta-analysis. J. Alzheimers Dis. 90, 1381\u20131393 (2022).","journal-title":"J. Alzheimers Dis."},{"key":"1165_CR194","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.938827","volume":"29","author":"M Warpechowski","year":"2023","unstructured":"Warpechowski, M., Warpechowski, J., Kulczynska-Przybik, A. & Mroczko, B. Biomarkers of activity-dependent plasticity and persistent enhancement of synaptic transmission in Alzheimer disease: a review of the current status. Med. Sci. Monit. 29, e938826 (2023).","journal-title":"Med. Sci. Monit."},{"key":"1165_CR195","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson, C. J. et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res. Ther. 13, 80\u201394 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"1165_CR196","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1007\/s00259-018-4031-2","volume":"45","author":"Z Walker","year":"2018","unstructured":"Walker, Z. et al. Clinical utility of FDG PET in Parkinson\u2019s disease and atypical parkinsonism associated with dementia. Eur. J. Nucl. Med. Mol. Imaging 45, 1534\u20131545 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1165_CR197","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00259-018-4035-y","volume":"45","author":"PJ Nestor","year":"2018","unstructured":"Nestor, P. J. et al. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur. J. Nucl. Med. Mol. Imaging 45, 1509\u20131525 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1165_CR198","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.27361","volume":"33","author":"T Simuni","year":"2018","unstructured":"Simuni, T. et al. Longitudinal change of clinical and biological measures in early Parkinson\u2019s disease: Parkinson\u2019s Progression Markers Initiative Cohort. Mov. Disord. 33, 771\u2013782 (2018).","journal-title":"Mov. Disord."},{"key":"1165_CR199","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/brain\/awz023","volume":"142","author":"A Whone","year":"2019","unstructured":"Whone, A. et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson\u2019s disease. Brain 142, 512\u2013525 (2019).","journal-title":"Brain"},{"key":"1165_CR200","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1602\/neurorx.1.2.189","volume":"1","author":"R Katz","year":"2004","unstructured":"Katz, R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1, 189\u2013195 (2004).","journal-title":"NeuroRx"},{"key":"1165_CR201","unstructured":"Food and Drug Administration. Expedited Programs for Serious Conditions \u2013 Drugs and Biologics https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/expedited-programs-serious-conditions-drugs-and-biologics (FDA, 2014)."},{"key":"1165_CR202","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016).","journal-title":"Nature"},{"key":"1165_CR203","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13195-022-00984-y","volume":"14","author":"SS Assuncao","year":"2022","unstructured":"Assuncao, S. S. et al. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer\u2019s disease. Alzheimers Res. Ther. 14, 54 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"1165_CR204","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S1474-4422(23)00508-2","volume":"23","author":"EM Reiman","year":"2024","unstructured":"Reiman, E. M., Cummings, J. L., Langbaum, J. B., Mattke, S. & Alexander, R. C. A chance to prevent Alzheimer\u2019s disease sooner than you think. Lancet Neurol. 23, 144\u2013145 (2024).","journal-title":"Lancet Neurol."},{"key":"1165_CR205","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14342","volume":"21","author":"P Aisen","year":"2024","unstructured":"Aisen, P. et al. The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer\u2019s disease based on clearcut biomarker evidence. Alzheimers Dement. 21, e14342 (2024).","journal-title":"Alzheimers Dement."},{"key":"1165_CR206","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s43587-024-00731-y","volume":"4","author":"J Therriault","year":"2024","unstructured":"Therriault, J. et al. Diagnosis of Alzheimer\u2019s disease using plasma biomarkers adjusted to clinical probability. Nat. Aging 4, 1529\u20131537 (2024).","journal-title":"Nat. Aging"},{"key":"1165_CR207","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade, E. et al. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res. Ther. 14, 191 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"1165_CR208","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/mds.27724","volume":"34","author":"JD Heiss","year":"2019","unstructured":"Heiss, J. D. et al. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson\u2019s disease. Mov. Disord. 34, 1073\u20131078 (2019).","journal-title":"Mov. Disord."},{"key":"1165_CR209","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/acn3.51164","volume":"7","author":"RN Alcalay","year":"2020","unstructured":"Alcalay, R. N. et al. Longitudinal measurements of glucocerebrosidase activity in Parkinson\u2019s patients. Ann. Clin. Transl. Neurol. 7, 1816\u20131830 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1165_CR210","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/mds.28472","volume":"36","author":"S Lerche","year":"2021","unstructured":"Lerche, S. et al. The mutation matters: CSF profiles of GCase, sphingolipids, \u03b1-synuclein in PD(GBA). Mov. Disord. 36, 1216\u20131228 (2021).","journal-title":"Mov. Disord."},{"key":"1165_CR211","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/acn3.325","volume":"3","author":"LH Meeter","year":"2016","unstructured":"Meeter, L. H. et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann. Clin. Transl. Neurol. 3, 623\u2013636 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1165_CR212","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/jnnp-2021-328547","volume":"93","author":"P Oeckl","year":"2022","unstructured":"Oeckl, P. et al. Serum GFAP differentiates Alzheimer\u2019s disease from frontotemporal dementia and predicts MCI-to-dementia conversion. J. Neurol. Neurosurg. Psychiatry 93, 659\u2013667 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1165_CR213","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/ene.12675","volume":"22","author":"JL Whitwell","year":"2015","unstructured":"Whitwell, J. L. et al. Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. Eur. J. Neurol. 22, 745\u2013752 (2015).","journal-title":"Eur. J. Neurol."},{"key":"1165_CR214","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.parkreldis.2019.02.004","volume":"63","author":"HP Muller","year":"2019","unstructured":"Muller, H. P. et al. Combined cerebral atrophy score in Huntington\u2019s disease based on atlas-based MRI volumetry: sample size calculations for clinical trials. Parkinsonism Relat. Disord. 63, 179\u2013184 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1165_CR215","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi, S. J. et al. Potential disease-modifying therapies for Huntington\u2019s disease: lessons learned and future opportunities. Lancet Neurol. 21, 645\u2013658 (2022).","journal-title":"Lancet Neurol."},{"key":"1165_CR216","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1212\/WNL.0000000000009760","volume":"95","author":"A Bejanin","year":"2020","unstructured":"Bejanin, A. et al. Longitudinal structural and metabolic changes in frontotemporal dementia. Neurology 95, e140\u2013e154 (2020).","journal-title":"Neurology"},{"key":"1165_CR217","doi-asserted-by":"publisher","first-page":"102842","DOI":"10.1016\/j.nicl.2021.102842","volume":"32","author":"E Gordon","year":"2021","unstructured":"Gordon, E., Bocchetta, M., Nicholas, J., Cash, D. M. & Rohrer, J. D. A comparison of automated atrophy measures across the frontotemporal dementia spectrum: implications for trials. Neuroimage Clin. 32, 102842 (2021).","journal-title":"Neuroimage Clin."},{"key":"1165_CR218","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.neurobiolaging.2011.09.007","volume":"32","author":"EM Reiman","year":"2011","unstructured":"Reiman, E. M. & Alzheimer\u2019s Disease Biomarkers Working Group for the Alliance for Aging, R. Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer\u2019s disease-modifying treatments. Neurobiol. Aging 32, S44\u2013S47 (2011).","journal-title":"Neurobiol. Aging"},{"key":"1165_CR219","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm. Sin. B 12, 3049\u20133062 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"1165_CR220","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3389\/fphar.2019.01482","volume":"10","author":"L Meunier","year":"2019","unstructured":"Meunier, L. & Larrey, D. Drug-induced liver injury: biomarkers, requirements, candidates, and validation. Front. Pharmacol. 10, 1482 (2019).","journal-title":"Front. Pharmacol."},{"key":"1165_CR221","doi-asserted-by":"publisher","first-page":"221","DOI":"10.14283\/jpad.2022.34","volume":"9","author":"J Cummings","year":"2022","unstructured":"Cummings, J. et al. Aducanumab: appropriate use recommendations update. J. Prev. Alzheimers Dis. 9, 221\u2013230 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1165_CR222","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings, J. et al. Lecanemab: appropriate use recommendations. J. Prev. Alzheimers Dis. 10, 362\u2013377 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1165_CR223","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","volume":"16","author":"LS Honig","year":"2024","unstructured":"Honig, L. S. et al. Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease. Alzheimers Res. Ther. 16, 105 (2024).","journal-title":"Alzheimers Res. Ther."},{"key":"1165_CR224","doi-asserted-by":"publisher","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","volume":"100","author":"F Alves","year":"2023","unstructured":"Alves, F., Kalinowski, P. & Ayton, S. Accelerated brain volume loss caused by anti-beta-amyloid drugs: a systematic review and meta-analysis. Neurology 100, e2114\u2013e2124 (2023).","journal-title":"Neurology"},{"key":"1165_CR225","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1474-4422(24)00335-1","volume":"23","author":"CRS Belder","year":"2024","unstructured":"Belder, C. R. S. et al. Brain volume change following anti-amyloid beta immunotherapy for Alzheimer\u2019s disease: amyloid-removal-related pseudo-atrophy. Lancet Neurol. 23, 1025\u20131034 (2024).","journal-title":"Lancet Neurol."},{"key":"1165_CR226","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080705","volume":"8","author":"MA Baptista","year":"2013","unstructured":"Baptista, M. A. et al. Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS ONE 8, e80705 (2013).","journal-title":"PLoS ONE"},{"key":"1165_CR227","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav0820","volume":"12","author":"MAS Baptista","year":"2020","unstructured":"Baptista, M. A. S. et al. LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Sci. Transl. Med. 12, eaav0820 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1165_CR228","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s41591-024-02973-0","volume":"30","author":"J Sevigny","year":"2024","unstructured":"Sevigny, J. et al. Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1\/2 trial interim results. Nat. Med. 30, 1406\u20131415 (2024).","journal-title":"Nat. Med."},{"key":"1165_CR229","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","volume":"377","author":"J Woodcock","year":"2017","unstructured":"Woodcock, J. & LaVange, L. M. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med. 377, 62\u201370 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1165_CR230","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.therap.2022.12.003","volume":"78","author":"M Roustit","year":"2023","unstructured":"Roustit, M. et al. Platform trials. Therapie 78, 29\u201338 (2023).","journal-title":"Therapie"},{"key":"1165_CR231","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","volume":"18","author":"Adaptive Platform Trials Coalition.","year":"2019","unstructured":"Adaptive Platform Trials Coalition. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat. Rev. Drug Discov. 18, 797\u2013807 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1165_CR232","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1001\/jama.2015.2316","volume":"313","author":"SM Berry","year":"2015","unstructured":"Berry, S. M., Connor, J. T. & Lewis, R. J. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 313, 1619\u20131620 (2015).","journal-title":"JAMA"},{"key":"1165_CR233","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/ana.26714","volume":"94","author":"M Quintana","year":"2023","unstructured":"Quintana, M. et al. Design and statistical innovations in a platform trial for amyotrophic lateral sclerosis. Ann. Neurol. 94, 547\u2013560 (2023).","journal-title":"Ann. Neurol."},{"key":"1165_CR234","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1093\/brain\/awad063","volume":"146","author":"T Foltynie","year":"2023","unstructured":"Foltynie, T. et al. Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson\u2019s disease. Brain 146, 2717\u20132722 (2023).","journal-title":"Brain"},{"key":"1165_CR235","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13195-022-01015-6","volume":"14","author":"J Cummings","year":"2022","unstructured":"Cummings, J., Montes, A., Kamboj, S. & Cacho, J. F. The role of basket trials in drug development for neurodegenerative disorders. Alzheimers Res. Ther. 14, 73 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"1165_CR236","doi-asserted-by":"publisher","first-page":"78","DOI":"10.14283\/jpad.2019.3","volume":"6","author":"R Vassar","year":"2019","unstructured":"Vassar, R. Editorial: implications for BACE1 inhibitor clinical trials: adult conditional BACE1 knockout mice exhibit axonal organization defects in the hippocampus. J. Prev. Alzheimers Dis. 6, 78\u201384 (2019).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1165_CR237","doi-asserted-by":"publisher","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","volume":"98","author":"N Mattsson-Carlgren","year":"2022","unstructured":"Mattsson-Carlgren, N. et al. Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology 98, e1137\u2013e1150 (2022).","journal-title":"Neurology"},{"key":"1165_CR238","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awaa276","volume":"143","author":"DN Soleimani-Meigooni","year":"2020","unstructured":"Soleimani-Meigooni, D. N. et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer\u2019s disease and other neurodegenerative diseases. Brain 143, 3477\u20133494 (2020).","journal-title":"Brain"},{"key":"1165_CR239","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/acn3.51238","volume":"8","author":"SJ Teipel","year":"2021","unstructured":"Teipel, S. J. et al. Association of PET-based stages of amyloid deposition with neuropathological markers of Abeta pathology. Ann. Clin. Transl. Neurol. 8, 29\u201342 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1165_CR240","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/alz.12466","volume":"18","author":"JA Syrjanen","year":"2022","unstructured":"Syrjanen, J. A. et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 18, 1128\u20131140 (2022).","journal-title":"Alzheimers Dement."},{"key":"1165_CR241","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2023.4719","volume":"81","author":"WS Brum","year":"2024","unstructured":"Brum, W. S. et al. Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial. JAMA Neurol. 81, 197\u2013200 (2024).","journal-title":"JAMA Neurol."},{"key":"1165_CR242","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IMW Verberk","year":"2022","unstructured":"Verberk, I. M. W. et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease-related blood-based biomarkers: results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group. Alzheimers Dement. 18, 1484\u20131497 (2022).","journal-title":"Alzheimers Dement."},{"key":"1165_CR243","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ana.26819","volume":"95","author":"JD Grill","year":"2024","unstructured":"Grill, J. D. et al. Eligibility rates among racially and ethnically diverse US participants in phase 2 and phase 3 placebo-controlled, double-blind, randomized trials of lecanemab and elenbecestat in early Alzheimer disease. Ann. Neurol. 95, 288\u2013298 (2024).","journal-title":"Ann. Neurol."},{"key":"1165_CR244","unstructured":"Food and Drug Administration. Diversity action plans to improve enrollment of participants from underrepresented populations in clinical studies. Draft Guidance for Industry https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies (FDA, 2024)."},{"key":"1165_CR245","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/alz.12773","volume":"19","author":"RJ Jutten","year":"2023","unstructured":"Jutten, R. J. et al. Why a clinical trial is as good as its outcome measure: a framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer\u2019s disease. Alzheimers Dement. 19, 708\u2013720 (2023).","journal-title":"Alzheimers Dement."},{"key":"1165_CR246","doi-asserted-by":"publisher","first-page":"8129","DOI":"10.1002\/alz.14250","volume":"20","author":"HH Feldman","year":"2024","unstructured":"Feldman, H. H. et al. A framework for translating tauopathy therapeutics: drug discovery to clinical trials. Alzheimers Dement. 20, 8129\u20138152 (2024).","journal-title":"Alzheimers Dement."},{"key":"1165_CR247","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson","year":"2023","unstructured":"Wilson, D. M. et al. Hallmarks of neurodegenerative diseases. Cell 186, 693\u2013714 (2023).","journal-title":"Cell"},{"key":"1165_CR248","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/brain\/awy146","volume":"141","author":"JL Robinson","year":"2018","unstructured":"Robinson, J. L. et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141, 2181\u20132193 (2018).","journal-title":"Brain"},{"key":"1165_CR249","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/alz.12814","volume":"19","author":"JB Toledo","year":"2023","unstructured":"Toledo, J. B. et al. Dementia with Lewy bodies: impact of co-pathologies and implications for clinical trial design. Alzheimers Dement. 19, 318\u2013332 (2023).","journal-title":"Alzheimers Dement."},{"key":"1165_CR250","first-page":"1234","volume":"90","author":"C Smith","year":"2019","unstructured":"Smith, C. et al. Neuropathology of dementia in patients with Parkinson\u2019s disease: a systematic review of autopsy studies. J. Neurol. Neurosurg. Psychiatry 90, 1234\u20131243 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1165_CR251","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/S2666-7568(23)00019-3","volume":"4","author":"E Nichols","year":"2023","unstructured":"Nichols, E. et al. The prevalence, correlation, and co-occurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementia. Lancet Healthy Longev. 4, e115\u2013e125 (2023).","journal-title":"Lancet Healthy Longev."},{"key":"1165_CR252","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12, 3400 (2021).","journal-title":"Nat. Commun."},{"key":"1165_CR253","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel, C. et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 76, 1035\u20131048 (2019).","journal-title":"JAMA Neurol."},{"key":"1165_CR254","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13195-023-01321-7","volume":"15","author":"JL Cummings","year":"2023","unstructured":"Cummings, J. L. et al. The therapeutic landscape of tauopathies: challenges and prospects. Alzheimers Res. Ther. 15, 168 (2023).","journal-title":"Alzheimers Res. Ther."},{"key":"1165_CR255","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","volume":"16","author":"Writing Group; Edavarone (MCI-186) ALS 19 Study Group.","year":"2017","unstructured":"Writing Group; Edavarone (MCI-186) ALS 19 Study Group.Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16, 505\u2013512 (2017).","journal-title":"Lancet Neurol."},{"key":"1165_CR256","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3109\/21678421.2014.959024","volume":"15","author":"K Abe","year":"2014","unstructured":"Abe, K. et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 610\u2013617 (2014).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"1165_CR257","unstructured":"Food and Drug Administration. Qualification Process for Drug Development Tools Guidance for Industry and FDA Staff https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/qualification-process-drug-development-tools-guidance-industry-and-fda-staff (2020)."},{"key":"1165_CR258","unstructured":"Food and Drug Administration. Biomarker qualification: evidentiary framework. Guidance for Industry and FDA staff. DRAFT GUIDANCE. https:\/\/www.fda.gov\/media\/119271\/download (FDA, 2018)."},{"key":"1165_CR259","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry 90, 870\u2013881 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1165_CR260","unstructured":"European Medicines Agency. Qualification Opinion of Alzheimer\u2019s Disease Novel Methodologies\/Biomarkers for PET Amyloid Imaging as a Biomarker for Enrichment for use in Regulatory Trials in Predementia Alzheimer\u2019s Disease https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/qualification-opinion-alzheimers-disease-novel-methodologies-biomarkers-use-cerebrospinal-fluid-amyloid-beta-1-42-and-t-tau-and-or-positron-emission-tomography-amyloid-imaging-positive-negative_en.pdf (EMA, 2012)."},{"key":"1165_CR261","unstructured":"European Medicine Agencies. Qualification Opinion on Dopamine Transporter Imaging as an Enrichment Biomarker for Parkinson\u2019s Disease Clinical Trials in Patients with Early Parkinsonian Symptoms. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/qualification-opinion-dopamine-transporter-imaging-enrichment-biomarker-parkinsons-disease-clinical-trials-patients-early-parkinsonian-symptoms_en.pdf (EMA, 2018)."},{"key":"1165_CR262","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3390\/ani10071199","volume":"10","author":"GS Ferreira","year":"2020","unstructured":"Ferreira, G. S., Veening-Griffioen, D. H., Boon, W. P. C., Moors, E. H. M. & van Meer, P. J. K. Levelling the translational gap for animal to human efficacy data. Animals 10, 1199 (2020).","journal-title":"Animals"},{"key":"1165_CR263","first-page":"108","volume":"2","author":"JJ Sabbagh","year":"2013","unstructured":"Sabbagh, J. J., Kinney, J. W. & Cummings, J. L. Alzheimer\u2019s disease biomarkers in animal models: closing the translational gap. Am. J. Neurodegener. Dis. 2, 108\u2013120 (2013).","journal-title":"Am. J. Neurodegener. Dis."},{"key":"1165_CR264","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1124\/dmd.112.050864","volume":"41","author":"X Liu","year":"2013","unstructured":"Liu, X. et al. Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processing. Drug Metab. Dispos. 41, 1319\u20131328 (2013).","journal-title":"Drug Metab. Dispos."},{"key":"1165_CR265","doi-asserted-by":"publisher","first-page":"261ra154","DOI":"10.1126\/scitranslmed.3009835","volume":"6","author":"YJ Yu","year":"2014","unstructured":"Yu, Y. J. et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci. Transl. Med. 6, 261ra154 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1165_CR266","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200785","volume":"217","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model. J. Exp. Med. 217, e20200785 (2020).","journal-title":"J. Exp. Med."},{"key":"1165_CR267","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.1002\/alz.13921","volume":"20","author":"SP Schauer","year":"2024","unstructured":"Schauer, S. P. et al. Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonism. Alzheimers Dement. 20, 5861\u20135888 (2024).","journal-title":"Alzheimers Dement."},{"key":"1165_CR268","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/alz.12318","volume":"17","author":"D Beckman","year":"2021","unstructured":"Beckman, D. et al. A novel tau-based rhesus monkey model of Alzheimer\u2019s pathogenesis. Alzheimers Dement. 17, 933\u2013945 (2021).","journal-title":"Alzheimers Dement."},{"key":"1165_CR269","doi-asserted-by":"publisher","first-page":"26239","DOI":"10.1073\/pnas.1902301116","volume":"116","author":"D Beckman","year":"2019","unstructured":"Beckman, D. et al. Oligomeric A\u03b2 in the monkey brain impacts synaptic integrity and induces accelerated cortical aging. Proc. Natl Acad. Sci. USA 116, 26239\u201326246 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1165_CR270","volume":"9","author":"SJ Sukoff Rizzo","year":"2023","unstructured":"Sukoff Rizzo, S. J. et al. Bridging the rodent to human translational gap: marmosets as model systems for the study of Alzheimer\u2019s disease. Alzheimers Dement. 9, e12417 (2023).","journal-title":"Alzheimers Dement."},{"key":"1165_CR271","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000507569","volume":"49","author":"JL Cummings","year":"2020","unstructured":"Cummings, J. L. Translational scoring of candidate treatments for Alzheimer\u2019s disease: a systematic approach. Dement. Geriatr. Cogn. Disord. 49, 22\u201337 (2020).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"1165_CR272","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","volume":"186","author":"AL Boxer","year":"2023","unstructured":"Boxer, A. L. & Sperling, R. Accelerating Alzheimer\u2019s therapeutic development: the past and future of clinical trials. Cell 186, 4757\u20134772 (2023).","journal-title":"Cell"},{"key":"1165_CR273","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/alz.13560","volume":"20","author":"E Sanchez","year":"2024","unstructured":"Sanchez, E. et al. Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: results from the Ontario Neurodegenerative Disease Research Initiative. Alzheimers Dement. 20, 1753\u20131770 (2024).","journal-title":"Alzheimers Dement."},{"key":"1165_CR274","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1212\/WNL.0000000000011774","volume":"96","author":"LG Friedman","year":"2021","unstructured":"Friedman, L. G. et al. Value-generating exploratory trials in neurodegenerative dementias. Neurology 96, 944\u2013954 (2021).","journal-title":"Neurology"},{"key":"1165_CR275","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo6764","volume":"8","author":"Y Iturria-Medina","year":"2022","unstructured":"Iturria-Medina, Y. et al. Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer\u2019s disease progression and heterogeneity. Sci. Adv. 8, eabo6764 (2022).","journal-title":"Sci. Adv."},{"key":"1165_CR276","volume":"8","author":"EM Vromen","year":"2022","unstructured":"Vromen, E. M. et al. CSF proteomic signature predicts progression to Alzheimer\u2019s disease dementia. Alzheimers Dement. 8, e12240 (2022).","journal-title":"Alzheimers Dement."},{"key":"1165_CR277","first-page":"109","volume":"4","author":"J Cummings","year":"2017","unstructured":"Cummings, J. & Fox, N. Defining disease modifying therapy for Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 4, 109\u2013115 (2017).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1165_CR278","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1093\/brain\/awad265","volume":"146","author":"N Vijiaratnam","year":"2023","unstructured":"Vijiaratnam, N. & Foltynie, T. How should we be using biomarkers in trials of disease modification in Parkinson\u2019s disease? Brain 146, 4845\u20134869 (2023).","journal-title":"Brain"},{"key":"1165_CR279","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.medj.2024.08.004","volume":"5","author":"Y Hu","year":"2024","unstructured":"Hu, Y. et al. Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer\u2019s disease. Med 5, 1206\u20131226 (2024).","journal-title":"Med"},{"key":"1165_CR280","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/jnnp-2020-323520","volume":"92","author":"IJ Swift","year":"2021","unstructured":"Swift, I. J. et al. Fluid biomarkers in frontotemporal dementia: past, present and future. J. Neurol. Neurosurg. Psychiatry 92, 204\u2013215 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1165_CR281","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fmed.2019.00223","volume":"6","author":"AV Morant","year":"2019","unstructured":"Morant, A. V., Jagalski, V. & Vestergaard, H. T. Labeling of disease-modifying therapies for neurodegenerative disorders. Front. Med. 6, 223 (2019).","journal-title":"Front. Med."},{"key":"1165_CR282","unstructured":"Food and Drug Administration. Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format. Guidance for Industry https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-studies-section-labeling-human-prescription-drug-and-biological-products-content-and-format (FDA, 2006)."},{"key":"1165_CR283","unstructured":"Food and Drug Administration. Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease. Guidance for Industry. https:\/\/www.fda.gov\/media\/117173\/download (FDA, 2018)."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01165-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01165-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01165-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:20:12Z","timestamp":1757154012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01165-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":283,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1038\/s41573-025-01165-w","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"20 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L.C. has provided consultation to Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP\/eqt, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, Sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. B.K.F. is a full-time employee of The Michael J. Fox Foundation for Parkinson\u2019s Research and has no conflicts of interest to disclose. I.L.B. has served on a Medical Advisory Board and has a consultancy agreement with Alector and Prevail Therapeutics\/Lilly. C.E.T. performed contract research for Acumen, ADx Neurosciences, AC Immune, Alamar, Aribio, Axon Neurosciences, Beckman\u2013Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Toyama, Vivoryon. C.E.T. is editor in chief of\n                      Alzheimer\u2019s Research & Therapy\n                      , and serves on editorial boards of\n                      Medidact Neurologie\n                      \/Springer, and\n                      Neurology\n                      :\n                      Neuroimmunology & Neuroinflammation\n                      ,\n                      Alzheimer\u2019s & Dementia\n                      and\n                      Molecular Neurodegeneration\n                      . K.R.W. is a full-time employee of Eisai. M.S. has served or serves on advisory boards for Arvakor, Eli Lilly, Novo Nordisk and Roche, has received speaker honoraria from Bioarctic, Genentech, Novo Nordisk, Eli Lilly, Roche and Triolabs and receives research support (paid to institution) from Alzpath, Beckman\u2013Coulter, Bioarctic, Gates Ventures, Novo Nordisk and Roche. He is a co-founder and stakeholder of Centile Bioscience and serves as Associate Editor of\n                      Alzheimer\u2019s Research & Therapy\n                      . B.D. has provided consultation to Prothena Biosciences. P.S. is a full-time employee of EQT Life Sciences (formerly LSP). He reports having received consultancy fees (paid to Vrije Universiteit Amsterdam) from AC Immune, Alzheon, BrainStorm Cell, FUJIFILM\/Toyama, Green Valley and Novo Nordisk.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}